Full-Time

Principal IS Business Systems Analyst

Process Development, Information Systems

Posted on 8/29/2025

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Biology & Biotech (3)
, ,
Required Skills
Machine Learning
Tableau
JIRA
Confluence
DevOps
Data Analysis
Requirements
  • Doctorate degree / Master's degree / Bachelor's degree and 12 to 17 years of experience in Infrastructure/IT or related field.
  • Excellent problem-solving skills and a passion for tackling complex challenges in data and analytics with technology
  • Experience leading data and analytics teams in a Scaled Agile Framework (SAFe)
  • Good interpersonal skills, good attention to detail, and ability to influence based on data and business value
  • Ability to build compelling business cases with accurate cost and effort estimations
  • Experienced in documenting technical processes, product specifications, etc., and writing user requirements and acceptance criteria in agile project management systems, such as Jira and Confluence.
  • Ability to explain sophisticated technical concepts to non-technical clients
  • Familiarity of Lab Information Systems within a GxP regulatory environment
  • Experience with Tableau, Spotfire or similar tools for dynamic visualizations and metrics for tracking users, instruments and site data.
Responsibilities
  • Establish an effective engagement model to collaborate with the Process Development Electronic Lab Notebook users to help realize business value through the application of emerging AI/ML technologies.
  • Actively engages with business users to analyze business needs, gather and document business and solution requirements guided by best practices in Holistic Lab, Instrument Data Acquisition, and Business Reporting requirements against the Enterprise Data Lake.
  • Serve as the technology product leader by leading and refining the long-term technology strategy for HLEE, including ELN (Electronic Lab Notebooks), Chromatography Data Systems, and other lab information systems. This includes defining the roadmap and prioritizing features aligned with business goals.
  • Lead and mentor junior team members to deliver on the needs of the business.
  • Collaborates with IS Architects and System Owners to design an integrated solution across HL, Enterprise Data Lake (EDL), Product Lifecycle Management (PLM), and lab instrument solutions.
  • Interact with business clients and technology management to create technology roadmaps, build cases, and drive DevOps to achieve the roadmaps.
  • Help to mature Agile operating principles through deployment of creative and consistent practices for user story development, robust testing and quality oversight, and focus on user experience.
  • Facilitate the breakdown of Epics into Features and Sprint-Sized User Stories and participate in backlog reviews with the development team.
  • Clearly express features in User Stories/requirements so all team members and partners understand how they fit into the product backlog.
  • Ensure Acceptance Criteria and Definition of Done are well-defined.
  • Become the domain expert in emerging technology capabilities by researching and implementing new tools and features, internal and external methodologies.
  • Provide input for governance discussions and help prepare materials to support executive alignment on technology strategy and investment.
  • Lead the voice of the customer assessment to define business processes and product needs.
  • Develop and implement effective product demonstrations for internal and external partners.
  • Maintain accurate documentation of configurations, processes, and changes.
Desired Qualifications
  • 5 – 8 years of domain knowledge in health and/or life sciences combined with Information Technology
  • Good overall understanding of business, manufacturing, and laboratory systems common in the process development and manufacturing labs, as well as the integration of these systems through applicable standards
  • Experience handling a globally distributed enterprise application platform
  • Depth or breadth of expertise with offerings within the Lab solution landscape – including ELN, inventory management, MES and scientific analysis tools
  • Understanding of FDA regulations governing computer system validation and operation in biotech manufacturing and laboratory areas
  • Strong analytic/critical-thinking and decision-making abilities.
  • Established business partnerships and IS governance practices involving senior business partners
  • Experience of DevOps, Continuous Integration, and Continuous Delivery methodology
  • Understanding of software systems strategy, governance, and infrastructure
  • Experience in managing product features for PI planning and developing product roadmaps and user journeys
  • Familiarity with low-code, no-code test automation software
  • Technical thought leadership
  • Experience in quality assurance and change control processes

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE